Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy

Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding specificity to CD20. It was the first therapeutic antibody approved for oncology patients and was the top-selling oncology drug for nearly a decade with sales reaching $8.58 billion in 2016. Since its initial approval...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierpont, Timothy M., Limper, Candice B., Richards, Kristy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994406/
https://www.ncbi.nlm.nih.gov/pubmed/29915719
http://dx.doi.org/10.3389/fonc.2018.00163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994406/
https://www.ncbi.nlm.nih.gov/pubmed/29915719
http://dx.doi.org/10.3389/fonc.2018.00163

Ejemplares similares